Modulation of Urokinase-type and Tissue-type Plasminogen Activator Occurs at an Early Stage of Progressing Stages of Chronic Venous Insufficiency

MANFRED PESCHEN¹, ALAN A. ROGERS², W. Y. JOHN CHEN² and WOLFGANG VANSCHEIDT¹

¹Department of Dermatology, University of Freiburg, Germany and ²Convatec Wound Healing Research Institute, Flintshire, UK

Recent observations of the protein and mRNA levels of late stages of CVI, such as lipodermatosclerosis and leg ulceration, have described an imbalance of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), possibly contributing to a breakdown of the extracellular matrix and formation of ulcers (9, 10).

Moreover, the well-known altered fibrinolytic activity in patients with CVI contributes to an increased activation of the plasminogen activator/plasmin system, which has been implicated in such diverse processes as angiogenesis, inflammatory reaction, wound healing and the control and activation of MMPs (11, 12). Although the localization of, for example, MMPs, TIMPs and other proteases by PCR, in situ hybridization or immunohistochemical techniques is important and useful for the understanding of the pathology of CVI, these techniques do not address the question “it may be there, but is it active?”

Plasminogen activators (PAs) are another important, endogenously produced, class of proteases that have been studied recently in chronic wounds (11, 13, 14). The aim of this investigation was therefore to determine the distribution pattern and activity level of the plasminogen activators uPA and tPA by in situ zymography in progressing stages of CVI, and to define their role in the development of CVI.

MATERIAL AND METHODS

Patients

The study group comprised 14 healthy volunteers (average age 52.8 years, age range 32 – 69 years, 7 females and 7 males) and 37 patients with 5 different clinical stages of CVI (mean age 60.3 years, age range 29 – 87 years, 25 females and 12 males), according to the severity of skin changes ascribed to venous disease (15). Doppler-sonography and photoplethysmography confirmed the clinical classification of CVI, which is based on a classification system that takes into account clinical signs (C), aetiology (E), anatomical distribution (A) and pathophysiological dysfunction (P), as described previously (CEAP classification) (16). A concomitant arteriosclerosis of the extremities was excluded by an ankle-brachial index >0.9. Six millimetre skin punch biopsies from clinically affected skin of the lower limb were taken under local anaesthesia (1% Scandicain) with primary wound closure, following informed consent from all subjects included in the study. All patients were informed about the risk of the biopsy inducing an ulcer. No patient developed an ulcer during the 3-month follow-up period. The biopsies from controls were site-matched relative to patient biopsies. Patients were assigned to one of six of the clinical stages of CVI, which were defined as follows: telangiectases (6 patients); stasis dermatitis (6 patients); hyperpigmentation (6 patients); lipodermatosclerosis (7 patients); and venous leg ulcer (12 patients) (15). Patients with leg ulcers were divided into 2 groups, each consisting of 6 patients; in one group biopsies were taken from
the leg ulcer margin, containing both adjacent skin and ulcer base tissue and in the other group biopsies were obtained from the leg ulcer base only. Immediately after biopsy, specimens were snap frozen in liquid nitrogen and stored at −80°C until further processing.

**In situ zymography.**

Plasminogen activator (PA) activity in unfixed frozen sections was assessed by *in situ* histological zymography, performed according to the method of Sappino et al. (17), with modifications (11). Ten μm thick sections were mounted on clean glass slides, allowed to dry at room temperature and stored at −20°C until use. This technique is based on the principle that the endogenous PAs are detected by an overlay, which contains plasminogen (the substrate for the endogenous PAs) and casein (a substrate for plasmin). Endogenous PA activity will convert the plasminogen in the overlay to plasmin (a general protease), which will degrade the casein and can be viewed experimentally. Therefore, an overlay mixture for the detection of PA activity, containing 5% (w/v) commercially available non-fat dry milk powder (Marvel®, Premier Beverages, Stafford, UK), 1% (w/v) agar (Bio-Rad Laboratories, Hercules, CA, USA) and 0.03 mg/ml human plasminogen (Quadratech, Epsom, UK), was prepared and maintained at approximately 50°C prior to use. This overlay was applied evenly over the biopsy sections, which had been pre-warmed to approximately 40°C on a heated platform. The section and added overlay were covered with 22×22 mm square glass cover slips to provide an overlay of even thickness and then were transferred briefly to a cold surface to allow the overlay to set. The slides were incubated at 37°C in humid chambers for 3–6 h to allow the zymograms to develop. To detect tPA activity, the plasminogen activator inhibitor amiloride (Sigma Chemicals Ltd, Poole, UK) (18) was added (200 μl 10 mmol/l) to the overlay. Control slide overlay gels contained no plasminogen. Photomicrographs (FP4 (125 ASA) film) were taken using dark field illumination (Nikon F-301 35 mm SLR camera system).

**Semiquantitative evaluation of plasminogen-dependent and -independent protease activity.**

Two independent double-blind investigators scored the profile of protease activity and the spatial localization in the skin biopsies. Activity was based on the extent of degradation of the overlay, i.e. the level of black seen in the overlay sections. Therefore, an overlay mixture for the detection of PA activity, containing 5% (w/v) commercially available non-fat dry milk powder (Marvel®, Premier Beverages, Stafford, UK), 1% (w/v) agar (Bio-Rad Laboratories, Hercules, CA, USA) and 0.03 mg/ml human plasminogen (Quadratech, Epsom, UK), was prepared and maintained at approximately 50°C prior to use. This overlay was applied evenly over the biopsy sections, which had been pre-warmed to approximately 40°C on a heated platform. The section and added overlay were covered with 22×22 mm square glass cover slips to provide an overlay of even thickness and then were transferred briefly to a cold surface to allow the overlay to set. The slides were incubated at 37°C in humid chambers for 3–6 h to allow the zymograms to develop. To detect tPA activity, the plasminogen activator inhibitor amiloride (Sigma Chemicals Ltd, Poole, UK) (18) was added (200 μl 10 mmol/l) to the overlay. Control slide overlay gels contained no plasminogen. Photomicrographs (FP4 (125 ASA) film) were taken using dark field illumination (Nikon F-301 35 mm SLR camera system).

**RESULTS**

Table I summarizes the protease activity profiles for all biopsies in progressing stages of CVI, and representative examples of the distribution patterns for the various stages are seen in Fig. 1. In normal skin, PA activity appeared predominantly as a punctate activity in the papillary layer of the dermis (Fig. 1A). Amiloride-containing overlays, representing the tPA activity, showed a decreased punctate activity (Fig. 1B). Control slides showed no non-plasminogen-dependent protease activity in normal skin (Fig. 1C).

Specimens of telangiectases again showed a distribution pattern of PA activity in the dermis, which was similar to that of healthy skin (Fig. 1A). Amiloride-exposed slides showed punctate tPA activity (5/6 patients) (Fig. 1B, Table I). The activity level of both uPA and tPA appeared to be decreased in comparison with normal skin. As with normal skin, no non-plasminogen-dependent activity was observed at this stage of CVI (Fig. 1C).

The CVI stage described as stasis dermatitis exhibited some punctate PA activity plus the appearance of a uniform activity (Fig. 1A), which appeared to be associated with the dermoepidermal junction. In the presence of amiloride the majority of this activity was inhibited suggesting that there was a reduced level of tPA activity (Fig. 1B) compared with normal skin. These biopsies, as with previous stages of CVI, exhibited no protease activity in the absence of plasminogen (Fig. 1C).

Biopsies from patients with hyperpigmentation showed a mostly punctate PA activity throughout the dermis (Fig. 1A), which was similar to the pattern of activity seen in healthy skin and patients with telangiectases. In particular, punctate tPA activity was present (Fig. 1B). No non-plasminogen-dependent activity was detected (Fig. 1C).

In lipodermatosclerosis, there appeared to be both a punctate and uniform distribution of PA activity (Fig. 1A). As with stasis dermatitis biopsies, a uniform band of PA activity was observed at the dermoepidermal junction (Fig. 1A), which was inhibited by amiloride (Fig. 1B), suggesting that this activity was uPA. Activity not inhibited

**Table I. The occurrence of protease activity, expressed as a ratio of patients showing activity, compared with the total number of patients investigated at each clinical stage (n = number of patients)**

<table>
<thead>
<tr>
<th>CVI-stage</th>
<th>Total plasminogen activator activity</th>
<th>tPA activity (without uPA activity)</th>
<th>Non-plasminogen-dependent protease activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal skin (n = 14)</td>
<td>14/14</td>
<td>14/14</td>
<td>0/14</td>
</tr>
<tr>
<td>Telangiectases (n = 6)</td>
<td>5/6</td>
<td>5/6</td>
<td>0/6</td>
</tr>
<tr>
<td>Stasis dermatitis (n = 6)</td>
<td>6/6</td>
<td>1/6</td>
<td>0/6</td>
</tr>
<tr>
<td>Hyperpigmentation (n = 6)</td>
<td>6/6</td>
<td>4/6</td>
<td>0/6</td>
</tr>
<tr>
<td>Lipodermatosclerosis (n = 7)</td>
<td>7/7</td>
<td>2/7</td>
<td>0/7</td>
</tr>
<tr>
<td>Leg ulcer base (n = 6)</td>
<td>6/6</td>
<td>6/6</td>
<td>6/6</td>
</tr>
<tr>
<td>Leg ulcer margin (n = 6)</td>
<td>6/6</td>
<td>4/6</td>
<td>3/6</td>
</tr>
</tbody>
</table>

CVI = chronic venous insufficiency; tPA = tissue-type plasminogen activator; uPA = urokinase type plasminogen activator.
by amiloride was detected in the deep tissue (Fig. 1B), however there was little of this activity in the upper dermis. As with normal skin biopsies and all previous stages of CVI, no non-plasminogen-dependent protease activity could be detected (Fig. 1C).

Specimens from the base of the venous leg ulcer revealed an increased level of protease activity throughout the tissue (Fig. 1A). Most of this activity was inhibited by amiloride (Fig. 1B). The majority of the remaining activity (Fig. 1B) was associated with the upper ulcer granulation tissue and was not inhibited by the absence of plasminogen, suggesting that this activity is plasminogen-independent (Fig. 1C).

Biopsies of leg ulcer margin presented a mixed pattern of PA activity, which reflected whether the specimen contained ulcer base or adjacent skin tissue. In the case of adjacent skin tissue (3/6), these biopsies showed an increased uniform or diffuse activity at all levels of the tissue similar to the pattern seen in lipodermatosclerosis. A large proportion of this activity could be inhibited by amiloride, indicating the presence of uPA. No non-plasminogen-dependent protease activity was detected in these biopsies of the ulcer margin tissue (data not shown). The remainder of the ulcer margin biopsies (3/6), presenting leg ulcer base tissue exhibited a pattern similar to the ulcer base biopsies.

Fig. 1. The spatial localization and activity level of urokinase-type-(uPA) and tissue-type-plasminogen activator (tPA) shows an early change in chronic venous insufficiency (e.g. stasis dermatitis) and marked changes in the later stages of lipodermatosclerosis and venous leg ulcer. Distribution pattern and activity level of uPA and tPA and non-plasminogen-dependent proteases in normal skin (n~14) and progressing stages of CVI, such as telangiectases (n~6), stasis dermatitis (n~6), hyperpigmentation (n~6), lipodermatosclerosis (n~7) and leg ulcer base (n~6). Cryosections of skin samples incubated with plasminogen-containing casein-agar overlay, showing total PA activity (A for each stage), plasminogen-containing casein-agar overlay with the addition of amiloride (uPA inhibitor) showing total PA activity without urokinase activity (B for each stage) and plasminogen-deficient casein-agar overlay (control), revealing plasminogen-independent activity (C for each stage) were analysed by in situ histological zymography, as described in the material and methods section (scale bar = 1 mm).
DISCUSSION

In this study we demonstrate that: (i) there are profound changes in the activity and spatial localization of both uPA and tPA during the progression of CVI; (ii) these changes begin early in CVI (e.g. stasis dermatitis); and (iii) the most striking changes in uPA and tPA activity occurs in the later stages of CVI, namely, lipodermatosclerosis and leg ulceration.

uPA and tPA are specific proteases at the top of the protease cascade in the conversion of the zymogen plasminogen to active plasmin, a general protease involved in the proteolysis of pericellular glycoproteins (19). uPA bound to a specific cellular receptor is involved in tissue remodelling processes and cell matrix interactions that are important in wound healing (20, 21). tPA, which is stored in endothelial cells, can be released acutely in the blood vessel lumen upon stimulation of the endothelium, stimulating fibrinolysis and preventing fibrin deposition (21).

Our in situ zymography results for normal skin and the earliest stage of CVI, clinically defined as telangiectases, show in accordance to previous studies that both uPA and tPA contributes to the total PA activity in normal skin (14, 22). Our studies provide evidence that, in situ, both these PAs are physiologically active. The punctate distribution pattern suggests blood vessel association of the PA activity. In the case of tPA, this activity is necessary for blood vessel patency (21).

Previous reports suggest that, in the inflammatory stage of stasis dermatitis, profound changes in the complex cascade of cytokines, adhesion molecules and growth factors take place (3). In vitro experiments showed that pro-inflammatory cytokines, such as tumour necrosis factor-alpha and interleukin-1beta induce a co-ordinated increase in uPA expression in keratinocytes with an increased pericellular plasmin-mediated proteolysis (23). Recently, we could show by immunofluorescence investigation of the extracellular matrix components laminin, fibronectin and tenasin, that increased fragmentation of the extracellular matrix could be seen first in biopsies from stasis dermatitis patients (24). Fibronectin fragments induce the expression of specific proteases, such as MMPs (25). Chronic wounds also contain elevated levels of MMPs (26, 27), and it has been shown that uPA is a major controller of MMP activation (28).

In comparison with normal skin and stasis dermatitis, our PA analysis suggests that biopsies of hyperpigmented skin may represent a “resting phase” in CVI, and is thus in agreement with other investigations studying growth factor and cytokeratin expression in hyperpigmented skin of CVI (5–7). We hypothesize that in the stage of hyperpigmentation, the most important region for the progressing pathophysiological changes is not in the overlying skin, but in the deeper layers of the skin, e.g. muscles, tendons and bones (29, 30).

Our results show a marked change in the distribution of PA activity in lipodermatosclerosis, clinically characterized by a strong level of fibroblast activation, which is in accordance with an increased platelet-derived growth factor expression, resulting in fibrosis and sclerosis of all structures of the affected area (7, 30, 31). In vitro studies have shown a promotive effect of this growth factor on the migration of human fibroblasts on titanium surfaces, which was correlated with the release of uPA from fibroblasts (32).

Reduced endothelial cell tPA activity is suggested as a major cause of decreased fibrinolytic activity in impaired wound healing and our results for venous leg ulcers clearly show a reduction in blood vessel-associated tPA activity (14). The expression of uPA is confined to the proliferative population of keratinocytes during epidermal wound healing, rather than to keratinocytes of the normal epidermis (23, 33), suggesting that the change in uPA activity at the dermo-epidermal junction in leg ulcer patients may stimulate the proliferation of the overlying keratinocytes (5, 13). Additionally, the enzymatic effect of uPA and the activation of plasmin may provide an environment that is more migratory for keratinocytes, thus inducing re-epithelialization (34). It has been shown by in situ hybridization that in poorly healing wounds, such as venous ulcers, uPA is expressed in keratinocytes (33). However, it may be that the degradative effects of high uPA activity levels are more important than the stimulatory effects of uPA on keratinocyte migration.

Previous studies have shown the presence of a non-plasminogen-dependent protease activity that appears specific for chronic ulcers, including pressure ulcers (11) and venous ulcers (14). This activity has not been detected in normal skin (11) or acute wounds (20). Results presented here confirm the presence of a non-plasminogen-dependent protease activity (9) and extend the data on this activity by showing that this activity does not appear until ulceration has occurred; it is not present in earlier stages of CVI.

We hypothesize that the balance or imbalance of the PA activity in the later stages of CVI is a central pathogenic factor for the development of venous leg ulceration. Overall, the down-regulation of uPA and tPA appears to be an important event in epidermal healing and restoration of a normal epidermal tissue structure (35).

REFERENCES

We thank Drs A. Glöggler and J. Hutchinson for providing technical assistance regarding the collaboration between both research centres involved in this study.


Acta Derm Venereol 80
35. Schaefer BM, Stark HJ, Fusseneg NE, Todd RF, 3rd, Kramer MD. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Exp Cell Res 1995; 220: 415 – 423.